Katherine French
Greenwich, CTNPI 1831642354
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $298,988 of the $307,629 with a category attached, or 97.2%. Galderma Laboratories, L.p. accounts for 97.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $130,814 and has fallen 73.5% since, to $34,616 in 2025.
Across 214 payments — averaging $1437.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$301K
- AbbVie$7K
- Pfizer$38
What the payments were for
- Speaking & faculty fees$298,98897%
- Travel & lodging$6,2772%
- Food & beverage$2,3641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 206 | $300,532 |
| AbbVie(2 entities) | 6 | $7,059 |
| Pfizer | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$3,218
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.